Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Residents at The Palace Nursing & Rehabilitation Center in Miami, Florida. Photo: Eva Marie Uzcategui/Bloomberg via Getty Images

Loopholes regarding the use of antipsychotics in patients with schizophrenia and two other conditions have allowed these powerful drugs to proliferate in understaffed nursing homes, a New York Times investigation revealed.

Why it matters: Antipsychotics are so powerful that they have been referred to as "chemical straitjackets," and can pose increased risk of death for elderly patients with dementia.

The big picture: Because antipsychotics are so powerful and potentially dangerous, the federal government requires that nursing homes report how many of their patients are being treated with the powerful drugs, the Times noted.

  • However, the government does not require the drugs' use to be publicly reported for residents with schizophrenia, Tourette’s syndrome or Huntington’s disease, thereby understating the true rate of use of antipsychotics in nursing homes.
  • At least 21% of nursing home residents are on antipsychotic drugs, and the share of residents with a schizophrenia diagnosis has increased to 11% from less than 7% since 2012, per the Times.
  • Caring for elderly patients is time and labor intensive, and nursing homes with staffing shortages have higher rates of antipsychotic drug use, indicating that homes are using the drugs to "subdue patients and avoid having to hire extra staff," noted the Times.
  • Hiding high rates of antipsychotic drug use can help a nursing home's rating from the government.
  • “It is unacceptable for a facility to inappropriately classify a resident’s diagnosis to improve their performance measures,” Catherine Howden, a spokeswoman for the Centers for Medicare and Medicaid Services, told the Times.

Of note: Cases of schizophrenia are nearly always diagnosed before the age of 40.

  • “People don’t just wake up with schizophrenia when they are elderly,” Michael Wasserman, a geriatrician and former nursing home executive, told the Times.

Go deeper

Pharmaceutical industry may avoid big losses in drug pricing deal

Illustration: Lazaro Gamio/Axios

The pharmaceutical industry is voicing opposition to the latest drug pricing deal.

Yes, but: The details matter. And the details as they stand suggest drug companies would still retain the power to set prices, and most drugs wouldn't be subject to government price negotiations.

Democrats circulate prescription drug framework

Speaker of the House Nancy Pelosi leaves a House Democratic caucus meeting at the U.S. Capitol on Nov. 2. Photo: Allison Shelley/Getty Images

Democrats' latest version of a prescription drug pricing deal limits Medicare negotiations to only 20 drugs by 2028 and gives some new drugs a longer period of time after they first come to market during which they're exempt from negotiations, according to a draft of the plan obtained by Axios.

Why it matters: It's still a deal on Medicare negotiations, a huge Democratic priority. But it's a much more moderate version than what most of the party had been pushing for.

Democrats' historic compromise on prescription drug prices

Illustration: Shoshana Gordon/Axios

Democrats have agreed on a top-level deal that would allow Medicare to negotiate the prices of some drugs. But moderates and pharma allies successfully took some of the bite out of the party's preferred approach.

Why it matters: If the deal ultimately becomes law, Democrats will be able to claim victory on what's been a major priority for years, and many Americans struggling to afford their medication would receive relief.